<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32246039</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>5941</StartPage><MedlinePgn>5941</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5941</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-62756-8</ELocationID><Abstract><AbstractText>Neuroinflammation is involved in the pathogenesis of amyotrophic lateral sclerosis (ALS), but only limited data are available on systematic peripheral and central immune cell profiles in ALS. We studied detailed immune profiles of 73 ALS patients and 48 healthy controls (controls) in peripheral blood by fluorescence-activated cell sorting as well as cytokine expression profiles in serum. In a subgroup of 16 ALS patients and 10 controls we additionally studied cerebrospinal fluid (CSF) samples. In peripheral blood, T cell subtypes presented a shift towards pro-inflammatory Th 1 and Th 17 cells whereas anti-inflammatory Th2 and T regulatory cells were decreased. Important players in innate immunity including distinct monocyte (Mo) and natural killer (NK) cell subtypes were changed in ALS&#xa0;patients compared to controls. Pro-inflammatory serum cytokines such as interleukin (IL)-1 beta, IL-6 and interferon-gamma (IFN-gamma) were increased and the anti-inflammatory cytokine IL-10 was decreased. Correlation analysis revealed moderate negative correlations between Th1 and Th17 to the ALS functional rating scale revised (ALSFRS-R) and to forced vital capacity. In CSF samples, no relevant alteration of the immune profile was found. In conclusion, the immune profile in ALS was shifted towards a Th1/Th17 cell-mediated pro-inflammatory immune response and correlated to disease severity and progression. Large prospective studies are needed to confirm these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Mengmeng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Neuroscience, University Hospital Carl Gustav Carus, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Rene</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0329-5644</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany. rene.guenther@uniklinikum-dresden.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany. rene.guenther@uniklinikum-dresden.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akg&#xfc;n</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Neuroscience, University Hospital Carl Gustav Carus, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziemssen</LastName><ForeName>Tjalf</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8799-8202</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Neuroscience, University Hospital Carl Gustav Carus, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020078" MajorTopicYN="N">Neurogenic Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058408" MajorTopicYN="N">Th1-Th2 Balance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058504" MajorTopicYN="N">Th17 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>R.G. has received honoraria from Biogen as an advisory board member and for lectures. K.A. received honoaria for presentations/advisory boards from Biogen Idec, Merck, Sanofi and Roche. A.H. received funding from the Innovationsfond des Gemeinsamen Bundesausschusses, the Helmholtz-Association and Hermann und Lilly Schilling-Stiftung f&#xfc;r medizinische Forschung im Stifterverband. He has received honoraria for presentations/advisory boards/ from Desitin and Biogen. He has received royalties from Elsevier Press. He serves as an editorial board member of BMC neurology. T.Z. received personal compensation from Almirall, Biogen Idec, Bayer, Celgene, Novartis, Roche, Sanofi, Teva for consulting services. Ziemssen received additional financial support for research activities from BAT, Biogen, Novartis, Roche, Teva, and Sanofi Aventis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32246039</ArticleId><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-62756-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-62756-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918&#x2013;934. doi: 10.1016/j.cell.2010.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.02.016</ArticleId><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annual review of neuroscience. 2004;27:723&#x2013;749. doi: 10.1146/annurev.neuro.27.070203.144244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.27.070203.144244</ArticleId><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J.-F., Zheng, O.-X., Xin, J.-G., Chen, H. H. &amp; Xin, J. J. How are necroptosis, immune dysfunction, and motoneuron death connected in amyotrophic lateral sclerosis? Neuroimmunology and Neuroinflammation4, 10.20517/2347-8659.2017.12 (2017).</Citation></Reference><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59. doi: 10.1016/j.neuron.2006.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.09.018</ArticleId><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998;23:249&#x2013;256. doi: 10.1002/(SICI)1098-1136(199807)23:3&lt;249::AID-GLIA7&gt;3.0.CO;2-#.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-1136(199807)23:3&lt;249::AID-GLIA7&gt;3.0.CO;2-#</ArticleId><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiology of disease. 2004;15:601&#x2013;609. doi: 10.1016/j.nbd.2003.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2003.12.012</ArticleId><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PloS one. 2012;7:e39216. doi: 10.1371/journal.pone.0039216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039216</ArticleId><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology. 2011;30:4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185827</ArticleId><ArticleId IdType="pubmed">21842586</ArticleId></ArticleIdList></Reference><Reference><Citation>Greter M, Merad M. Regulation of microglia development and homeostasis. Glia. 2013;61:121&#x2013;127. doi: 10.1002/glia.22408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22408</ArticleId><ArticleId IdType="pubmed">22927325</ArticleId></ArticleIdList></Reference><Reference><Citation>Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annual review of immunology. 2009;27:669&#x2013;692. doi: 10.1146/annurev.immunol.021908.132557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.021908.132557</ArticleId><ArticleId IdType="pubmed">19132917</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson, N., Facciponte, D., Bradley, W. &amp; Stommel, E. Cytokine expression levels in ALS: A potential link between inflammation and BMAA-triggered protein misfolding. Cytokine &amp; growth factor reviews, 10.1016/j.cytogfr.2017.05.001 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28532674</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C, et al. TNF and sTNFR1/2 plasma levels in ALS patients. Journal of neuroimmunology. 2008;194:123&#x2013;131. doi: 10.1016/j.jneuroim.2007.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.10.028</ArticleId><ArticleId IdType="pubmed">18083240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurology(R) neuroimmunology &amp; neuroinflammation. 2016;3:e244. doi: 10.1212/NXI.0000000000000244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Poloni M, et al. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 2000;287:211&#x2013;214. doi: 10.1016/S0304-3940(00)01177-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01177-0</ArticleId><ArticleId IdType="pubmed">10863032</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Gao L, Zang D. Elevated Levels of IFN-gamma in CSF and Serum of Patients with Amyotrophic Lateral Sclerosis. PloS one. 2015;10:e0136937. doi: 10.1371/journal.pone.0136937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136937</ArticleId><ArticleId IdType="pmc">PMC4557946</ArticleId><ArticleId IdType="pubmed">26332465</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, et al. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA neurology. 2013;70:1505&#x2013;1511. doi: 10.1001/jamaneurol.2013.4646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4646</ArticleId><ArticleId IdType="pubmed">24145899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekizawa T, et al. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J. Neurol. Sci. 1998;154:194&#x2013;199. doi: 10.1016/S0022-510X(97)00228-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00228-1</ArticleId><ArticleId IdType="pubmed">9562310</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P, et al. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflammation. 2014;11:94. doi: 10.1186/1742-2094-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-94</ArticleId><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain and behavior. 2017;7:e00637. doi: 10.1002/brb3.637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.637</ArticleId><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L, et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta neuropathologica. 2016;132:391&#x2013;411. doi: 10.1007/s00401-016-1548-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1548-y</ArticleId><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PloS one. 2017;12:e0182002. doi: 10.1371/journal.pone.0182002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, et al. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA neurology. 2017;74:1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, et al. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. Journal of neuroimmunology. 2009;210:73&#x2013;79. doi: 10.1016/j.jneuroim.2009.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.02.012</ArticleId><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni A, et al. Th17 Cell Response in SOD1G93A Mice following Motor Nerve Injury. Mediators of inflammation. 2016;2016:6131234. doi: 10.1155/2016/6131234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/6131234</ArticleId><ArticleId IdType="pmc">PMC4852359</ArticleId><ArticleId IdType="pubmed">27194826</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M, et al. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clinical immunology. 2013;148:79&#x2013;88. doi: 10.1016/j.clim.2013.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2013.04.010</ArticleId><ArticleId IdType="pubmed">23665549</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO molecular medicine. 2013;5:64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain: a journal of neurology. 2011;134:1293&#x2013;1314. doi: 10.1093/brain/awr074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. The Lancet. Neurology. 2018;17:681&#x2013;688. doi: 10.1016/S1474-4422(18)30176-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30176-5</ArticleId><ArticleId IdType="pubmed">29934198</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi medical journal: the journal of Medical Association of Malawi. 2012;24:69&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576830</ArticleId><ArticleId IdType="pubmed">23638278</ArticleId></ArticleIdList></Reference><Reference><Citation>Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology16, 505-512, 10.1016/s1474-4422(17)30115-1 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle &amp; nerve. 2002;26:459&#x2013;470. doi: 10.1002/mus.10191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10191</ArticleId><ArticleId IdType="pubmed">12362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Current opinion in neurology. 2018;31:635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon MS, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C. Inflammation. Immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle &amp; nerve. 2019;59:10&#x2013;22. doi: 10.1002/mus.26289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26289</ArticleId><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, et al. Evidence for peripheral immune activation in amyotrophic lateral sclerosis. J. Neurol. Sci. 2014;347:90&#x2013;95. doi: 10.1016/j.jns.2014.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.09.025</ArticleId><ArticleId IdType="pubmed">25312013</ArticleId></ArticleIdList></Reference><Reference><Citation>Langrish CL, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005;201:233&#x2013;240. doi: 10.1084/jem.20041257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041257</ArticleId><ArticleId IdType="pmc">PMC2212798</ArticleId><ArticleId IdType="pubmed">15657292</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 1998;8:275&#x2013;283. doi: 10.1016/S1074-7613(00)80533-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80533-6</ArticleId><ArticleId IdType="pubmed">9529145</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau J, et al. Immunobiology of dendritic cells. Annual review of immunology. 2000;18:767-+. doi: 10.1146/annurev.immunol.18.1.767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.18.1.767</ArticleId><ArticleId IdType="pubmed">10837075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, et al. Alterations of T cell subsets in ALS: a systemic immune activation? Acta neurologica Scandinavica. 2012;125:260&#x2013;264. doi: 10.1111/j.1600-0404.2011.01528.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2011.01528.x</ArticleId><ArticleId IdType="pubmed">21651502</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends in immunology. 2001;22:633&#x2013;640. doi: 10.1016/S1471-4906(01)02060-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4906(01)02060-9</ArticleId><ArticleId IdType="pubmed">11698225</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen N, Odum N, Urso B, Lanier LL, Spee P. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PloS one. 2012;7:e31959. doi: 10.1371/journal.pone.0031959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031959</ArticleId><ArticleId IdType="pmc">PMC3284517</ArticleId><ArticleId IdType="pubmed">22384114</ArticleId></ArticleIdList></Reference><Reference><Citation>Caligiuri MA. Human natural killer cells. Blood. 2008;112:461&#x2013;469. doi: 10.1182/blood-2007-09-077438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-09-077438</ArticleId><ArticleId IdType="pmc">PMC2481557</ArticleId><ArticleId IdType="pubmed">18650461</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi FD, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nature reviews. Immunology. 2011;11:658&#x2013;671. doi: 10.1038/nri3065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3065</ArticleId><ArticleId IdType="pmc">PMC3620656</ArticleId><ArticleId IdType="pubmed">21941294</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen KE, Mathew SO, Borgmann K, Ghorpade A, Mathew PA. A novel ligand on astrocytes interacts with natural cytotoxicity receptor NKp44 regulating immune response mediated by NK cells. PloS one. 2018;13:e0193008. doi: 10.1371/journal.pone.0193008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0193008</ArticleId><ArticleId IdType="pmc">PMC5814005</ArticleId><ArticleId IdType="pubmed">29447242</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel T, et al. Human CD56bright NK Cells: An Update. Journal of immunology. 2016;196:2923&#x2013;2931. doi: 10.4049/jimmunol.1502570.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1502570</ArticleId><ArticleId IdType="pubmed">26994304</ArticleId></ArticleIdList></Reference><Reference><Citation>Airas L, et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clinical and experimental immunology. 2008;151:235&#x2013;243. doi: 10.1111/j.1365-2249.2007.03555.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2007.03555.x</ArticleId><ArticleId IdType="pmc">PMC2276950</ArticleId><ArticleId IdType="pubmed">18062798</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, et al. Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurology(R) neuroimmunology &amp; neuroinflammation. 2016;3:e242. doi: 10.1212/NXI.0000000000000242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000242</ArticleId><ArticleId IdType="pmc">PMC4897983</ArticleId><ArticleId IdType="pubmed">27308304</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Perdiguero E, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518:547&#x2013;551. doi: 10.1038/nature13989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13989</ArticleId><ArticleId IdType="pmc">PMC5997177</ArticleId><ArticleId IdType="pubmed">25470051</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J, Sisodia SS, Ransohoff RM. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nature neuroscience. 2011;14:1227&#x2013;1235. doi: 10.1038/nn.2923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2923</ArticleId><ArticleId IdType="pubmed">21952260</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson N, Facciponte D, Bradley W, Stommel E. Cytokine expression levels in ALS: A potential link between inflammation and BMAA-triggered protein misfolding. Cytokine &amp; growth factor reviews. 2017;37:81&#x2013;88. doi: 10.1016/j.cytogfr.2017.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2017.05.001</ArticleId><ArticleId IdType="pubmed">28532674</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, et al. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiology of disease. 2003;14:74&#x2013;80. doi: 10.1016/s0969-9961(03)00087-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0969-9961(03)00087-1</ArticleId><ArticleId IdType="pubmed">13678668</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, et al. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta neurologica Scandinavica. 2010;122:425&#x2013;429. doi: 10.1111/j.1600-0404.2010.01333.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2010.01333.x</ArticleId><ArticleId IdType="pubmed">20219021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing G, Dequen F, Soucy G, Julien JP. Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2006;26:11397&#x2013;11402. doi: 10.1523/JNEUROSCI.0602-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0602-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674545</ArticleId><ArticleId IdType="pubmed">17079668</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, et al. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation. 2010;7:76. doi: 10.1186/1742-2094-7-76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-76</ArticleId><ArticleId IdType="pmc">PMC2992053</ArticleId><ArticleId IdType="pubmed">21062492</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology. 2005;65:1958&#x2013;1960. doi: 10.1212/01.wnl.0000188907.97339.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000188907.97339.76</ArticleId><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilanus TBM, et al. The predictive value of respiratory function tests for non-invasive ventilation in amyotrophic lateral sclerosis. Respiratory research. 2017;18:144. doi: 10.1186/s12931-017-0624-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-017-0624-8</ArticleId><ArticleId IdType="pmc">PMC5526316</ArticleId><ArticleId IdType="pubmed">28743265</ArticleId></ArticleIdList></Reference><Reference><Citation>Sta M, et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiology of disease. 2011;42:211&#x2013;220. doi: 10.1016/j.nbd.2011.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.01.002</ArticleId><ArticleId IdType="pubmed">21220013</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain, behavior, and immunity. 2011;25:1025&#x2013;1035. doi: 10.1016/j.bbi.2010.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebischer J, et al. Elevated levels of IFNgamma and LIGHT in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. European journal of neurology. 2012;19:752&#x2013;759. doi: 10.1111/j.1468-1331.2011.03623.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03623.x</ArticleId><ArticleId IdType="pubmed">22221541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology. 2013;8:888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunther R, et al. Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset. Frontiers in pharmacology. 2017;8:17. doi: 10.3389/fphar.2017.00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00017</ArticleId><ArticleId IdType="pmc">PMC5281550</ArticleId><ArticleId IdType="pubmed">28197100</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonges L, et al. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia. 2014;62:217&#x2013;232. doi: 10.1002/glia.22601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22601</ArticleId><ArticleId IdType="pubmed">24311453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingor P, et al. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Frontiers in neurology. 2019;10:293. doi: 10.3389/fneur.2019.00293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00293</ArticleId><ArticleId IdType="pmc">PMC6446974</ArticleId><ArticleId IdType="pubmed">30972018</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurology(R) neuroimmunology &amp; neuroinflammation. 2015;2:e100. doi: 10.1212/NXI.0000000000000100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000100</ArticleId><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Frontiers in aging neuroscience. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Lyon MS, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune-modulating therapies. Muscle &amp; nerve. 2019;59:23&#x2013;33. doi: 10.1002/mus.26288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26288</ArticleId><ArticleId IdType="pubmed">29979478</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurology(R) neuroimmunology &amp; neuroinflammation. 2018;5:e465. doi: 10.1212/nxi.0000000000000465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/nxi.0000000000000465</ArticleId><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KW, et al. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Annals of neurology. 2018;84:361&#x2013;373. doi: 10.1002/ana.25302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25302</ArticleId><ArticleId IdType="pmc">PMC6175096</ArticleId><ArticleId IdType="pubmed">30048006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon MS, et al. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients. Journal of neurochemistry. 2014;131:206&#x2013;218. doi: 10.1111/jnc.12814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12814</ArticleId><ArticleId IdType="pubmed">24995608</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>